Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-09 |
2024-03 |
-0.12 |
-0.14 |
-0.02 |
-16.67% |
2024-03-06 |
2023-12 |
-0.09 |
-0.1 |
-0.01 |
-11.11% |
2024-03-06 |
2023-12 |
-0.09 |
N/A |
N/A |
N/A |
2023-11-09 |
2023-09 |
-0.12 |
-0.09 |
0.03 |
25.00% |
2023-11-09 |
2023-09 |
-0.12 |
N/A |
N/A |
N/A |
2023-08-08 |
2023-06 |
-0.13 |
-0.14 |
-0.01 |
-7.69% |
Date |
Firm |
Action |
From |
To |
2023-08-27 |
Craig-Hallum |
Upgrade |
|
Buy |
2023-08-08 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-05-09 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-03-08 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2023-01-26 |
SVB Leerink |
Upgrade |
|
Outperform |
2022-04-27 |
Craig-Hallum |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2024-01-30 |
EDICK PAUL RAYMOND |
Chief Executive Officer |
3.82M |
Stock Award(Grant) |
2023-11-19 |
HALKUFF DAWN |
Director |
0.00 |
Purchase |
2024-01-30 |
HECHT BETH P |
Officer |
1.55M |
Stock Award(Grant) |
2024-03-17 |
JOHNSON JOHN H |
Director |
751.41K |
Conversion of Exercise of derivative security |
2024-01-30 |
JOHNSON KENNETH ERLAND |
Officer |
446.86K |
Stock Award(Grant) |
2023-11-13 |
PERSKY MARLA S |
Director |
0.00 |
Purchase |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Blackrock Inc. |
9.33M |
24.46M |
6.76% |
2023-06-29 |
Vanguard Group Inc |
6.95M |
18.21M |
5.03% |
2023-06-29 |
Caxton Corporation |
5.64M |
14.78M |
4.09% |
2023-06-29 |
Stonepine Capital Management, LLC |
5.50M |
14.41M |
3.98% |
2023-06-29 |
BioImpact Capital LLC |
3.97M |
10.41M |
2.88% |
2023-06-29 |
Geode Capital Management, LLC |
2.68M |
7.03M |
1.94% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
4.11M |
10.76M |
2.97% |
2023-08-30 |
iShares Russell 2000 ETF |
3.04M |
6.91M |
2.20% |
2023-07-30 |
Invesco Global Opportunities Fund |
2.00M |
5.22M |
1.45% |
2023-06-29 |
Vanguard Extended Market Index Fund |
1.93M |
5.06M |
1.40% |
2023-07-30 |
Fidelity Small Cap Index Fund |
1.21M |
3.15M |
0.88% |
2023-08-30 |
iShares Russell 2000 Growth ETF |
1.10M |
2.49M |
0.80% |